Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23FN2O2.ClH |
Molecular Weight | 402.89 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC1=CC=C(C=C1)C(=O)CN2CCC(CN3CC4=CC=CC=C4C3=O)CC2
InChI
InChIKey=BDPRUATYXHSLAM-UHFFFAOYSA-N
InChI=1S/C22H23FN2O2.ClH/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27;/h1-8,16H,9-15H2;1H
Molecular Formula | C22H23FN2O2 |
Molecular Weight | 366.4286 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CYR-101 (MIN-101) is a cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). MIN-101 also shows binding affinity for a1-adrenergic receptors but low or no affinity for muscarinic, cholinergic, and
histaminergic receptors. MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The drug is in phase II clinical trials for the treatment of Schizophrenia.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28750582 |
7.53 nM [Ki] | ||
Target ID: Q5BJF2 Gene ID: 27346.0 Gene Symbol: TMEM97 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28750582 |
8.19 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28750582
Curator's Comment: A statistically significant difference in PANSS negative factor score was observed, with lower scores for the MIN-101 32 mg/day and 64 mg/day groups compared with the placebo group.
After at least 5 days' withdrawal from all antipsychotic medication, Schizophrenia patients were randomly assigned to receive 32 mg/day or 64 mg/day of oral CYR-101 (MIN-101) for 12 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28750582
CYR-101 (MIN-101) has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:05:40 GMT 2023
by
admin
on
Sat Dec 16 14:05:40 GMT 2023
|
Record UNII |
Y1S6FQ4I5T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
359625-80-2
Created by
admin on Sat Dec 16 14:05:40 GMT 2023 , Edited by admin on Sat Dec 16 14:05:40 GMT 2023
|
PRIMARY | |||
|
21078079
Created by
admin on Sat Dec 16 14:05:40 GMT 2023 , Edited by admin on Sat Dec 16 14:05:40 GMT 2023
|
PRIMARY | |||
|
100000183348
Created by
admin on Sat Dec 16 14:05:40 GMT 2023 , Edited by admin on Sat Dec 16 14:05:40 GMT 2023
|
PRIMARY | |||
|
SUB197737
Created by
admin on Sat Dec 16 14:05:40 GMT 2023 , Edited by admin on Sat Dec 16 14:05:40 GMT 2023
|
PRIMARY | |||
|
Y1S6FQ4I5T
Created by
admin on Sat Dec 16 14:05:40 GMT 2023 , Edited by admin on Sat Dec 16 14:05:40 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|